Prosperity Financial Group Inc. Lowers Holdings in Pfizer Inc. (NYSE:PFE)

Prosperity Financial Group Inc. cut its position in Pfizer Inc. (NYSE:PFE) by 5.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,782 shares of the biopharmaceutical company’s stock after selling 517 shares during the quarter. Prosperity Financial Group Inc.’s holdings in Pfizer were worth $233,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the stock. Natural Investments LLC bought a new position in shares of Pfizer in the 4th quarter worth $534,000. Donaldson Capital Management LLC increased its holdings in shares of Pfizer by 1.2% in the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock worth $947,000 after buying an additional 410 shares during the last quarter. Staley Capital Advisers Inc. increased its holdings in shares of Pfizer by 3.5% in the 4th quarter. Staley Capital Advisers Inc. now owns 2,150,418 shares of the biopharmaceutical company’s stock worth $57,051,000 after buying an additional 73,594 shares during the last quarter. Miller Financial Services LLC bought a new position in shares of Pfizer in the 4th quarter worth $431,000. Finally, King Luther Capital Management Corp grew its holdings in shares of Pfizer by 1.4% during the 4th quarter. King Luther Capital Management Corp now owns 2,535,085 shares of the biopharmaceutical company’s stock valued at $67,256,000 after purchasing an additional 34,070 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on PFE. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Wolfe Research began coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Finally, Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Trading Down 2.4 %

NYSE:PFE opened at $26.00 on Wednesday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company’s 50-day simple moving average is $26.29 and its 200 day simple moving average is $27.19. The firm has a market capitalization of $147.33 billion, a P/E ratio of 18.44, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.62%. The ex-dividend date of this dividend was Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.